National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Thyroid dysfunction (TD) represents an extrahepatic manifestation of chronic hepatitis C. This study aimed to assess TD incidence and association with disease severity, pretreatment viral load, pegylated interferon alpha 2a or 2b formulations and response to treatment in chronic hepatitis C patients treated with pegylated interferon alpha and Ribavirin. TD was prospectively evaluated in 226 euthyroid chronic hepatitis C Egyptian patients treated with pegylated interferon-alpha and Ribavirin for 48 weeks at weeks 0,4,12, 24, 36 and 48 of treatment and within 6 months after treatment using serum free thyroxine, thyroid-stimulating hormone. The disease severity and response to therapy were evaluated using METAVIR system and polymerase chain reaction test respectively. Twenty six treated patients (11.5%) developed TD (16 hypothyroidism, seven hyperthyroidism and three biphasic thyroiditis). 14 patients with TD achieved sustained viral response. 8/26 (30.8%) TD spontaneously reversed after treatment cessation and 18 cases required therapy. TD was not associated with pretreatment viral load, severity of liver fibrosis, interferon-alpha formulations or response to treatment. We conclude that Interferon-alpha and ribavirin therapy possibly induces TD in chronic hepatitis C patients. TD does not associate with pretreatment virological parameter, severity of liver disease or virological outcome.
Citations |
 |
 |
 |
 |
